NEWS HIGHLIGHTSMedia Articles Related to Zelnorm (Tegaserod)
Irritable Bowel Syndrome (IBS) Symptoms, Diet, Treatment, and Test Source: MedicineNet Chronic Pain Specialty [2017.09.22] Title: Irritable Bowel Syndrome (IBS) Symptoms, Diet, Treatment, and Test Category: Diseases and Conditions Created: 2/25/2002 12:00:00 AM Last Editorial Review: 9/22/2017 12:00:00 AM
IBS-D (Irritable Bowel Syndrome with Diarrhea) Source: MedicineNet Constipation Specialty [2017.09.22] Title: IBS-D (Irritable Bowel Syndrome with Diarrhea) Category: Diseases and Conditions Created: 8/10/2016 12:00:00 AM Last Editorial Review: 9/22/2017 12:00:00 AM
Irritable Bowel Syndrome (IBS) Quiz: Test Your Medical IQ Source: MedicineNet Laxatives For Constipation Specialty [2017.09.19] Title: Irritable Bowel Syndrome (IBS) Quiz: Test Your Medical IQ Category: MedicineNet Quiz Created: 10/12/2015 12:00:00 AM Last Editorial Review: 9/19/2017 7:30:12 PM
Irritable Bowel Syndrome in Children (IBS) Source: MedicineNet dicyclomine Specialty [2017.03.21] Title: Irritable Bowel Syndrome in Children (IBS) Category: Diseases and Conditions Created: 6/24/2009 12:00:00 AM Last Editorial Review: 3/21/2017 12:00:00 AM
Irritable Bowel Syndrome (IBS) Source: MedicineNet alosetron Specialty [2017.03.16] Title: Irritable Bowel Syndrome (IBS) Category: Symptoms and Signs Created: 10/16/2013 12:00:00 AM Last Editorial Review: 3/16/2017 12:00:00 AM
Published Studies Related to Zelnorm (Tegaserod)
Influence of tegaserod on proximal gastric tone and on the perception of gastric distention in functional dyspepsia. [2011.02] BACKGROUND: Abnormalities in gastric sensorimotor function (hypersensitivity to distention and impaired meal accommodation) have been implicated in the pathophysiology of functional dyspepsia (FD).In the subgroup with normal gastric emptying, tegaserod 6 mg b.i.d enhanced gastric accommodation.
Long-term tegaserod treatment for dysmotility-like functional dyspepsia: results of two identical 1-year cohort studies. [2010.03] BACKGROUND: Functional dyspepsia (FD) is a chronic disorder that adversely affects health-related quality of life (HRQoL). Published information on its long-term management is minimal and treatment options are limited. AIM: The aim of this study was to evaluate safety, efficacy and HRQoL with tegaserod 6 mg twice daily over 1 year in women with FD who completed one of two 6-week, randomized, placebo-controlled, double-blind studies... CONCLUSIONS: The long-term safety profile of tegaserod in women with FD was consistent with that of short-term treatment and accompanied by improvements in HRQoL, work productivity and symptom relief. These long-term results add to the clinical experience with FD and support the potential value of a 5-HT(4) agonist in the management of FD.
Long-term tegaserod treatment for dysmotility-like functional dyspepsia: results
of two identical 1-year cohort studies. [2010] 6-week, randomized, placebo-controlled, double-blind studies... CONCLUSIONS: The long-term safety profile of tegaserod in women with FD was
A randomized, controlled, double-blind trial of the adjunct use of tegaserod in whole-dose or split-dose polyethylene glycol electrolyte solution for colonoscopy preparation. [2008.08] BACKGROUND: Problems of compliance, quality, and safety of colon preparation regimens have prompted continued investigation with alternative forms of cleansing. OBJECTIVE: To evaluate the efficacy of tegaserod as an adjunct to a polyethylene glycol electrolyte solution (PEG-E), given as a whole dose or split dose, in colonoscopy preparation... CONCLUSIONS: Tegaserod has a marginal effect on the quality of colonoscopy preparation when used as an adjuvant to PEG-E. The split-dose PEG-E was superior to the whole-dose PEG-E and resulted in better colon cleansing, adherence, and tolerance.
Tegaserod treatment for dysmotility-like functional dyspepsia: results of two randomized, controlled trials. [2008.08] OBJECTIVES: Therapies for dysmotility-like functional dyspepsia (FD) are limited. We studied tegaserod, a selective serotonin type 4 receptor agonist, in patients with FD... CONCLUSIONS: Some improvement in dysmotility-like FD was observed with tegaserod treatment. The clinical implication of this improvement is uncertain.
Clinical Trials Related to Zelnorm (Tegaserod)
A Treatment Investigational New Drug (tIND) Program of Tegaserod in Women With Irritable Bowel Syndrome With Constipation or With Chronic Idiopathic Constipation [No longer available]
To provide tegaserod to eligible women adult patients who did not have satisfactory
improvement of their irritable bowel syndrome with constipation (IBS-C) or chronic
idiopathic constipation (CIC) symptoms with other available treatment(s) and / or patients
who had satisfactory improvement of their symptoms with prior tegaserod treatment for IBS-C
or CIC.
Effect of Tegaserod on Gastric Emptying in Patients With Diabetic Gastroparesis [Terminated]
This study will assess gastric emptying in patients with symptoms of diabetic gastroparesis
treated with tegaserod over 2 weeks.
The Effects of Tegaserod Vs. Placebo on Whole Gut Transit Time in Patients With Chronic Constipation and Dyspepsia [Withdrawn]
To demonstrate the effects of tegaserod on gastrointestinal scintigraphic orocecal transit
in female patients with CC and upper GI symptoms of dyspepsia
Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain. [Terminated]
This study will evaluate the safety and efficacy of Tegaserod in opioid-induced constipation
(OIC) in patients with non-cancer pain.
Patients who enter this study PRIOR to the core study (CHTF919N2201) interim analysis (IA)
receive the treatment as follows:
Patients on tegaserod 6 mg twice daily (b. i.d.) or 12 mg once daily (o. d.) in the core study
will remain on the same dose in the extension (double-blind).
Patients on placebo during the core study will receive tegaserod 12 mg o. d. (open-label)
Patients who enter this study AFTER the core study interim analysis will receive the
selected tegaserod dose regimen (open-label) determined by the core study IA.
Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain. [Terminated]
This study will evaluate the safety and efficacy of Tegaserod in opioid-induced constipation
in patients with non-cancer pain.
Patients who enter this study PRIOR to the core study (CHTF919N2201) interim analysis
receive the treatment as follows:
Patients will be randomly assigned to receive open label tegaserod 6 mg b. i.d. or tegaserod
12 mg o. d. using an allocation ratio of 1: 1.
Patients who enter this study AFTER the core study interim analysis receive the treatment as
follows:
Patients will be assigned to receive the selected tegaserod dose regimen (as determined by
the core study interim analysis) in an open label fashion.
|